v3.26.3
Condensed Consolidated Statements Of Cash Flows (Unaudited) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Operating Activities    
Net Income (Loss) $ 109 $ 144
Non-cash reconciliation adjustments:    
Unrealized (gains) losses on derivative instruments (Note 2) 535 68
Depreciation, amortization and accretion (Note 16) 285 208
Nuclear decommissioning trust funds (gain) loss, net (excluding interest and fees) (Note 6) (88) (112)
Nuclear fuel amortization (Note 7) 73 71
Deferred income taxes 14 44
Stock-based compensation (Note 13) 120 42
(Gain) loss on sales of assets, net (Note 17) (66) (36)
Other (Note 16) 30 38
Changes in assets and liabilities:    
Accounts receivable (70) (57)
Inventory, net (14) 35
Other assets 23 202
Accounts payable and accrued liabilities 61 (91)
Accrued interest 109 36
Collateral received (posted), net (68) (7)
Cash settlement of stock-based awards (Note 13) (500) 0
Other liabilities (63) (161)
Net cash provided by (used in) operating activities 490 424
Investing Activities    
Property, plant and equipment expenditures (Note 7) (348) (72)
Nuclear fuel expenditures (Note 7) (101) (94)
Nuclear decommissioning trust funds investment purchases (Note 6) (564) (1,852)
Nuclear decommissioning trust funds investment sale proceeds (Note 6) 530 1,827
Cornerstone Acquisition, net (Note 17) (2,569) 0
Proceeds from the sale of assets (Note 17) 73 40
Other 16 (5)
Net cash provided by (used in) investing activities (2,963) (156)
Financing Activities    
Debt issuances (Note 10) 4,000 0
Debt repayments (Note 10) (1,222) (13)
Deferred financing costs (59) (29)
Revolving credit facility borrowings (Note 10) 500 75
Revolving credit facility repayments (Note 10) (500) (75)
Share repurchases (Note 15) (502) (103)
Tax payments related to net-settled stock-based awards (Note 13) (141) 0
Other (6) 9
Net cash provided by (used in) financing activities 2,070 (136)
Net increase (decrease) in cash and cash equivalents and restricted cash and cash equivalents (403) 132
Beginning of period cash and cash equivalents and restricted cash and cash equivalents 752 365
End of period cash and cash equivalents and restricted cash and cash equivalents $ 349 $ 497